Site-specific functional roles of the Factor X activation peptide in the intrinsic tenase-mediated Factor X activation. 2022

Amalie Carnbring Bonde, and Sofie Rosenørn Hansen, and Eva Johansson, and Jais Rose Bjelke, and Jacob Lund
Research & Early Development, Novo Nordisk A/S, Måløv, Denmark.

The conversion of zymogen Factor X (FX) to an active protease involves the removal of a 52-residue long activation peptide (AP). Through site-directed mutagenesis, we investigate the role of the AP and demonstrate that the high abundance of proline residues is important for efficient proteolysis of FX. Moreover, we identify an essential interaction site for Factor IXa (FIXa) between residues 22 and 30 (AP numbering) and find that the residues between 31 and 41 may provide an important interaction site for the intrinsic tenase complex, composed of Factor IXa (FIXa) and Factor VIIIa (FVIIIa). Finally, we suggest that the carbohydrate chain at Asn-39 restricts the activator specificity, as elimination of this glycosylation site increases the activation rate for activation by FIXa and FXa.

UI MeSH Term Description Entries
D007700 Kinetics The rate dynamics in chemical or physical systems.
D009363 Neoplasm Proteins Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm. Proteins, Neoplasm
D010455 Peptides Members of the class of compounds composed of AMINO ACIDS joined together by peptide bonds between adjacent amino acids into linear, branched or cyclical structures. OLIGOPEPTIDES are composed of approximately 2-12 amino acids. Polypeptides are composed of approximately 13 or more amino acids. PROTEINS are considered to be larger versions of peptides that can form into complex structures such as ENZYMES and RECEPTORS. Peptide,Polypeptide,Polypeptides
D003546 Cysteine Endopeptidases ENDOPEPTIDASES which have a cysteine involved in the catalytic process. This group of enzymes is inactivated by CYSTEINE PROTEINASE INHIBITORS such as CYSTATINS and SULFHYDRYL REAGENTS.
D005170 Factor X Storage-stable glycoprotein blood coagulation factor that can be activated to factor Xa by both the intrinsic and extrinsic pathways. A deficiency of factor X, sometimes called Stuart-Prower factor deficiency, may lead to a systemic coagulation disorder. Autoprothrombin III,Coagulation Factor X,Stuart Factor,Stuart-Prower Factor,Blood Coagulation Factor X,Factor 10,Factor Ten,Stuart Prower Factor,Factor X, Coagulation
D015949 Factor IXa Activated form of factor IX. This activation can take place via the intrinsic pathway of blood coagulation by the action of factor XIa and calcium, or via the extrinsic pathway by the action of factor VIIa, thromboplastin, and calcium. Factor IXa serves to activate factor X to Xa by cleaving the arginyl-leucine peptide bond in factor X. Coagulation Factor IXa,Factor IX, Activated,Blood Coagulation Factor IX, Activated,Factor 9A,Factor Nine A,Activated Factor IX,Factor IXa, Coagulation

Related Publications

Amalie Carnbring Bonde, and Sofie Rosenørn Hansen, and Eva Johansson, and Jais Rose Bjelke, and Jacob Lund
February 2024, Journal of theoretical biology,
Amalie Carnbring Bonde, and Sofie Rosenørn Hansen, and Eva Johansson, and Jais Rose Bjelke, and Jacob Lund
December 2005, The Journal of biological chemistry,
Amalie Carnbring Bonde, and Sofie Rosenørn Hansen, and Eva Johansson, and Jais Rose Bjelke, and Jacob Lund
August 2016, Scientific reports,
Amalie Carnbring Bonde, and Sofie Rosenørn Hansen, and Eva Johansson, and Jais Rose Bjelke, and Jacob Lund
July 2007, Biochemistry,
Amalie Carnbring Bonde, and Sofie Rosenørn Hansen, and Eva Johansson, and Jais Rose Bjelke, and Jacob Lund
April 1992, The Journal of biological chemistry,
Amalie Carnbring Bonde, and Sofie Rosenørn Hansen, and Eva Johansson, and Jais Rose Bjelke, and Jacob Lund
December 2017, Journal of theoretical biology,
Amalie Carnbring Bonde, and Sofie Rosenørn Hansen, and Eva Johansson, and Jais Rose Bjelke, and Jacob Lund
November 2020, Thrombosis and haemostasis,
Amalie Carnbring Bonde, and Sofie Rosenørn Hansen, and Eva Johansson, and Jais Rose Bjelke, and Jacob Lund
July 1972, Biochimica et biophysica acta,
Amalie Carnbring Bonde, and Sofie Rosenørn Hansen, and Eva Johansson, and Jais Rose Bjelke, and Jacob Lund
August 1994, Journal of biochemistry,
Amalie Carnbring Bonde, and Sofie Rosenørn Hansen, and Eva Johansson, and Jais Rose Bjelke, and Jacob Lund
September 1998, Blood,
Copied contents to your clipboard!